共 50 条
Racial and ethnic disparities in access to total neoadjuvant therapy for rectal cancer
被引:0
|作者:
Chan, Michelle
[1
]
Rajasekar, Ganesh
[2
]
Arnow, Katherine D.
[2
]
Wagner, Todd H.
[2
,3
]
Dawes, Aaron J.
[1
,2
]
机构:
[1] Stanford Univ, Sch Med, Dept Surg, Sect Colon & Rectal Surg, Stanford, CA 94305 USA
[2] Stanford Surg Policy Improvement Res & Educ Ctr, Dept Surg, Stanford, CA USA
[3] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA
来源:
关键词:
PREOPERATIVE CHEMORADIOTHERAPY;
OPEN-LABEL;
OUTCOMES;
CHEMOTHERAPY;
SURGERY;
D O I:
10.1016/j.surg.2024.06.022
中图分类号:
R61 [外科手术学];
学科分类号:
摘要:
Background: Total neoadjuvant therapy has revolutionized the treatment of locally advanced rectal cancer and quickly become the new standard of care. Whether patients from all racial and ethnic groups have had equal access to these potential benefits, however, remains unknown. Methods: We identified all adults diagnosed with locally advanced rectal cancer in California who underwent neoadjuvant chemotherapy and radiation from 2010 to 2020 using the California Cancer Registry. We used logistic regression to estimate the predicted probability of receiving total neoadjuvant therapy as opposed to traditional chemoradiotherapy for each racial and ethnic group and used a time-race interaction to evaluate trends in access to total neoadjuvant therapy over time. We also compared survival by racial and ethnic group and total neoadjuvant therapy status using Kaplan-Meier plots and Cox proportional hazards models. Results: In total, 6,856 patients met inclusion criteria. Overall, 36.6% of patients received total neoadjuvant therapy in 2010 compared with 66.3% in 2020. Latino patients were significantly less likely than non-Latino White patients to undergo total neoadjuvant therapy ; however, there was no difference in the rate of growth in total neoadjuvant therapy over time between racial and ethnic groups. Non-Latino Black patients appeared to have lower risk-adjusted survival compared with non-Latino White patients, although not among patients who underwent total neoadjuvant therapy . Conclusion: Access to total neoadjuvant therapy has increased significantly over time in California with no apparent difference in the rate of growth between racial and ethnic groups. We found no evidence of racial or ethnic disparities in survival among patients treated with total neoadjuvant therapy, suggesting that increasing access to high-quality cancer care may also improve health equity. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:1058 / 1064
页数:7
相关论文